Jing Xu

Jing Xu

Auto-generated profile, based on publicly available information

Jing Xu

Department of Gastroenterology and Hepatology Guangzhou Digestive Disease Center Guangzhou First People’s Hospital School of Medicine South China University of Technology Guangzhou 510180 China gzhosp.cn

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2021 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
HXHao-Ming Xu
Hao-Ming Xu
HHHongli Huang
Hongli Huang
YZYoulian Zhou
Youlian Zhou
HZHai-Lan Zhao
Hai-Lan Zhao
JXJing Xu
Jing Xu
YNYuqiang Nie
Yuqiang Nie
Gut dysbacteriosis is closely related to various intestinal and extraintestinal diseases. Fecal microbiota transplantation (FMT) is a biological therapy that entails transferring the gut microbiota from healthy individuals to patients in order to reconstruct the intestinal microflora in the latter. It has been proved to be an effective treatment for recurrent Clostridium difficile infection. Studies show that the gut microbiota plays an important role in the pathophysiology of neurological and psychiatric disorders through the microbiota-gut-brain axis. Therefore, reconstruction of the healthy gut microbiota is a promising new strategy for treating cerebral diseases. We have reviewed the latest research on the role of gut microbiota in different nervous system diseases as well as FMT in the context of its application in neurological, psychiatric, and other nervous system-related diseases (Parkinsons disease, Alzheimers disease, multiple sclerosis, epilepsy, autism spectrum disorder, bipolar disorder, hepatic encephalopathy, neuropathic pain, etc.).

13 December 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JLJin Liu
Jin Liu
YYYukang Yuan
Yukang Yuan
JXJing Xu
Jing Xu
KXKui Xiao
Kui Xiao
YXYing Xu
Ying Xu
HZHui Zheng
Hui Zheng
β transducin repeat-containing protein (β-TrCP) is a Skp1-Cul1-F-box ubiquitin ligase, which plays important roles in controlling numerous signaling pathways. Notably, β-TrCP induces ubiquitination and degradation of inhibitor of NF-κB (IκBα), thus triggering activation of NF-κB signaling. Here, we unexpectedly find that β-TrCP restricts TRAF6-IKK signaling upstream of IκBα induced by lipopolysaccharide (LPS). In LPS-Toll-like receptor 4 (TLR4) pathway, protein kinase D1 (PKD1) is essential for activation of TRAF6-IKK-IκBα signaling including TRAF6 ubiquitination, IKK phosphorylation and subsequent IκBα degradation. We found that LPS promotes binding of β-TrCP to PKD1, and results in downregulation of PKD1 and recovery of IκBα protein level. Knockdown of β-TrCP blocks LPS-induced downregulation of PKD1. Supplement of enough PKD1 in cells inhibits recovery of IκBα protein levels during LPS stimulation. Furthermore, we demonstrate that β-TrCP inhibits LPS-induced TRAF6 ubiquitination and IKK phosphorylation. Taken together, our findings identify β-TrCP as an important negative regulator for upstream signaling of IκBα in LPS pathway, and therefore renew the understanding of the roles of β-TrCP in regulating TLRs inflammatory signaling.

8 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
HXHao-Ming Xu
Hao-Ming Xu
YZYoulian Zhou
Youlian Zhou
JXJing Xu
Jing Xu
YLYing-Fei Li
Ying-Fei Li
CZChong Zhao
Chong Zhao
YNYuqiang Nie
Yuqiang Nie
Background and Aim. The enteric microbiota is able to cross‐talk with factors involved in the blockade of programmed cell death protein 1 (PD‐1) and also plays an important role in the predisposition and onset of inflammatory bowel disease (IBD). The current study used a mouse model of experimental colitis to determine the pathogenic connection between PD‐1 inhibition, gut microbiota, and IBD. Methods. Colitis was induced in mice using 2,4,6‐trinitrobenzene‐sulfonic acid (TNBS), and mice were subsequently treated with either a PD‐1 inhibitor or 5‐amino‐salicylic acid (ASA) as a positive control. Body weight, disease activity index (DAI), colon length, and tissue damage were evaluated, and the enteric microbiota was profiled using high‐throughput 16S rRNA sequencing of fecal samples from the experimental mice. Results. TNBS caused mice to experience IBD‐like symptoms, which were attenuated by the PD‐1 inhibitor, as indicated by a decrease in DAI scores (p = 0.0002). Furthermore, in this mouse model of IBD, PD‐1 inhibition improved the alpha diversity as well as restored the beta diversity of the enteric microbiome. It also significantly enriched the abundance of short‐chain fatty acid‐ (SCFA‐) producing bacteria of the Firmicutes (p < 0.05) and Bacteroidetes (p < 0.05) phyla but depopulated Proteobacteria (p < 0.05). Conclusion. PD‐1 inhibition can partly mitigate TNBS‐induced colitis and restore the enteric microbiota by enriching the abundance of SCFA‐producing bacteria.

Verified
Dataset
Open access
YWYan Wang
Yan Wang
ZLZhiqiang Liu
Zhiqiang Liu
JZJu-Hong Zhou
Ju-Hong Zhou
TWTao Wang
Tao Wang
SWSuna Wang
Suna Wang
JXJing Xu
Jing Xu